SCHEMBL2271748

SCHEMBL2271748

O=C(Nc1cc(-c2ccccc2)ccc1C(=O)O)c1cc2ccccc2s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.76
ACLY P53396 5/20 0.59
HDAC2 Q92769 2/20 0.54
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
TMIGD3 P0DMS9 1/20 0.53
ADORA1 P30542 1/20 0.53
STAT1 P42224 1/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
BCL2L1 Q07817 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1309213 0.85 PRSS12 (0.64) HDAC1ACLYHDAC2HDAC3HDAC4
SCHEMBL2276877 0.82 HDAC1 (0.52) HDAC1ACLYHDAC2HDAC3HDAC4
SCHEMBL2277719 0.82 HDAC1 (0.52) HDAC1ACLYHDAC2HDAC3HDAC4
SCHEMBL8162705 0.81 HDAC1 (0.56) HDAC1ACLYHDAC2HDAC3HDAC4
SCHEMBL2275537 0.80 HDAC1 (0.78) HDAC1ACLYPRSS12
SCHEMBL2271045 0.79 ACLY (0.81) HDAC1ACLYHDAC2HDAC3PRSS12
SCHEMBL2269832 0.78 HDAC3 (0.74) HDAC1ACLYHDAC3DHODH
SCHEMBL2270222 0.77 DHODH (0.77) HDAC1ACLYHDAC2HDAC3DHODH
SCHEMBL2275453 0.77 ACLY (0.76) HDAC1ACLYHDAC2HDAC3DHODH
SCHEMBL5535632 0.76 TP53 (0.58) HDAC1ACLYHDAC2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HDAC1 71/4885ACLY 653/4885HDAC2 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.